Want to see IN:VIYASH full AI Analyst Report?
VIYASH Stock Chart & Stats
₹210.65
-₹3.94(-2.00%)
At close: 4:00 PM EST
₹210.65
-₹3.94(-2.00%)
Day’s Range― - ―
52-Week Range₹167.45 - ₹297.90
Previous CloseN/A
VolumeN/A
Average Volume (3M)119.95K
Market Cap
₹110.01B
Enterprise Value₹85.83K
Total Cash (Recent Filing)₹2.70B
Total Debt (Recent Filing)₹4.90B
Price to Earnings (P/E)77.5
Beta1.24
Next Earnings
Aug 11, 2026Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.25
Shares Outstanding436,875,500
10 Day Avg. Volume209,903
30 Day Avg. Volume119,946
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)2.72
Price to Sales (P/S)2.32
P/FCF Ratio61.41
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)9.3
Revenue Forecast (FY)₹38.99B
Bulls Say, Bears Say
Bulls Say
Strong Recent Revenue GrowthA sustained, large revenue rebound materially improves scale and product adoption potential. Doubling revenue in 2026 indicates commercial traction and a larger revenue base that supports durable R&D and SG&A absorption, enabling longer-term margin expansion if growth persists.
Improving Operating MarginsMeaningful margin recovery to mid-teens operating levels suggests stronger pricing power and cost control versus prior loss years. If these margins reflect structural improvements (mix, efficiencies), they support sustainable cash generation and reinvestment capacity over the medium term.
Material De‑leveraging And Stronger Balance SheetA much lower leverage ratio increases financial flexibility to fund organic growth, absorb shocks, or pursue strategic investments. Improved equity and reduced debt lower interest burden risk and enhance resilience through industry cycles over the next several quarters.
Bears Say
Historical Earnings VolatilityPrior multi‑year volatility and loss periods indicate the company’s earnings base is not yet proven. This raises execution risk that recent improvements could reverse, making medium-term forecasts and capital allocation plans more uncertain for investors and stakeholders.
Weak Cash Conversion Vs. Net IncomePersistently low cash conversion signals sensitivity to working capital and capex, limiting ability to self‑fund growth, pay dividends, or rapidly reduce debt. This structural gap increases reliance on external financing and raises execution risk if revenue or margins ebb.
Margin Stability Not Yet EstablishedWide margin swings through recent cycles imply the cost structure or product mix remains vulnerable. Without evidence margins can be sustained through slower growth, profitability could compress, undermining long‑term free cash flow and return metrics.
Viyash Scientific News
VIYASH FAQ
What was Viyash Scientific Limited’s price range in the past 12 months?
Viyash Scientific Limited lowest stock price was ₹167.45 and its highest was ₹297.90 in the past 12 months.
What is Viyash Scientific Limited’s market cap?
Viyash Scientific Limited’s market cap is ₹110.01B.
When is Viyash Scientific Limited’s upcoming earnings report date?
Viyash Scientific Limited’s upcoming earnings report date is Aug 11, 2026 which is in 5 days.
How were Viyash Scientific Limited’s earnings last quarter?
Viyash Scientific Limited released its earnings results on May 19, 2026. The company reported ₹1.17 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Viyash Scientific Limited overvalued?
According to Wall Street analysts Viyash Scientific Limited’s price is currently Overvalued.
Does Viyash Scientific Limited pay dividends?
Viyash Scientific Limited pays a Annually dividend of ₹0.5 which represents an annual dividend yield of N/A. See more information on Viyash Scientific Limited dividends here
What is Viyash Scientific Limited’s EPS estimate?
Viyash Scientific Limited’s EPS estimate is 2.
How many shares outstanding does Viyash Scientific Limited have?
Viyash Scientific Limited has 436,875,500 shares outstanding.
What happened to Viyash Scientific Limited’s price movement after its last earnings report?
Viyash Scientific Limited reported an EPS of ₹1.17 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.373%.
Which hedge fund is a major shareholder of Viyash Scientific Limited?
Currently, no hedge funds are holding shares in IN:VIYASH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Viyash Scientific Limited
Viyash Scientific Limited is a global veterinary healthcare company with operations spanning Europe, Asia, and other international markets. It specializes in developing and supplying finished dosage forms for a range of therapeutic applications, including nutritional support, pain relief, parasite control, antibiotic treatments, and gut health solutions. These products cater to various animals like livestock, poultry, and domestic pets. Additionally, the company extends its expertise through analytical testing and specialized veterinary formulation services. Originally established as Sequent Scientific Limited, the company officially adopted the name Viyash Scientific Limited in January 2026. Founded in 1985, its corporate headquarters are situated in Hyderabad, India. Currently, Viyash Scientific Limited functions as a subsidiary of CA Harbor Investments.
Technical Analysis
Akums Drugs and Pharmaceuticals Limited
―
Alembic Pharmaceuticals Limited
―
Caplin Point Laboratories Limited
―
Glenmark Life Sciences Limited
―
Strides Pharma Science Ltd
―